Brief: Femasys Inc Provides Strategic Update On Its Femaseed Pivotal Trial Design
20/10/2022 13:34
Oct 20 (Reuters) - Femasys Inc FEMY.O :
* FEMASYS INC. PROVIDES STRATEGIC UPDATE ON ITS FEMASEED®
PIVOTAL
TRIAL DESIGN TO EXPEDITE CLINICAL PROGRAM ADVANCEMENT
* FEMASYS INC - UPDATED FEMASEED LOCAL ARTIFICIAL
INSEMINATION
TRIAL DESIGN FOCUSES ON MALE FACTOR INFERTILITY IN PATIENT TRIAL
RECRUITMENT
* FEMASYS INC - STUDY ENROLLMENT IS EXPECTED TO BE
COMPLETED IN
2023 FOR FEMASEED LOCAL DE NOVO CLINICAL TRIAL
Source text for Eikon: ID:nGNX7jcySC
Further company coverage: FEMY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Femasys
See all newsBrief: Femasys - Files For Resale Of Up To 28,124,997 Shares Of Common Stock - SEC Filing
Brief: Femasys Announces FDA Approval Of Modular Pma Submission Approach For Fembloc
Femasys Inc reports results for the quarter ended June 30 - Earnings Summary
Femasys Inc expected to post a loss of $1.30 a share - Earnings Preview
Femasys Inc expected to post a loss of $1.30 a share - Earnings Preview